Riverside Health & Rehabilitation Center Responds to Community Need for Parkinson's Disease Care With Its Advanced Program
April 07, 2022 18:00 ET | National Health Care Associates
EAST HARTFORD, Conn., April 07, 2022 (GLOBE NEWSWIRE) -- Riverside Health & Rehabilitation Center now offers advanced programming for Parkinson's Disease patients. The program provides an...
Picture1.jpg
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
April 05, 2022 01:05 ET | Curium
ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug...
TheCorner.png
Boxing Community Fights Back Against the Impact of COVID-19
November 19, 2021 10:42 ET | The Corner Boxing Club
BOULDER, Colo., Nov. 19, 2021 (GLOBE NEWSWIRE) -- When Carrie Barry, founder of the Corner Boxing Club and former national amateur boxing champion, opened her gym in 2014 she had a vision. She...
TheCorner.png
Unite to Fight V - Boulder’s Only Amateur Charity Boxing Tournament is Back!
November 03, 2021 14:13 ET | The Corner Boxing Club
The Corner Boxing Club Hosts 36 Contenders Uniting to Fight for 30+ NonprofitsSaturday, November 20, 2021, 6:30-10:00PMBoulder Theater, 2032 14th Street, Boulder, CO 80302. BOULDER, Colo., Nov. 03,...
First Patient Treated with the DopaFuse® Delivery System
October 27, 2021 02:58 ET | SynAgile Corporation
WILSON, Wyo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- SynAgile is pleased to announce treatment of the first patient with the DopaFuse Delivery System in the SCOL (Study of Continuous Oral Levodopa)...
retro.jpg
Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)
October 06, 2021 07:00 ET | Retrotope
Treatment with RT001 Results in Statistically Significant Improvements in Overall Survival and Progression Free Survival for INAD Patients as Compared to Control Benefits Supported by Totality of...
retro.jpg
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
June 30, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope to Present at H.C. Wainwright Global Life Sciences Conference
March 03, 2021 16:05 ET | Retrotope
LOS ALTOS, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
February 25, 2021 07:00 ET | Retrotope
Company Currently Conducting Late-Stage Clinical Trials in Both Infantile Neuroaxonal Dystrophy (INAD) and Friedreich’s Ataxia (FA) RT001 also Granted Fast Track Designation by FDA in FA; Orphan Drug...
Prothena_RGB_fullcolor.jpg
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
February 24, 2021 16:05 ET | Prothena Corporation plc
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital...